TrialBMC urology2017

Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial.

John W Peabody et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.